StreetInsider.com News Articles

Form 4 TG THERAPEUTICS, INC. For: Aug 06 Filed by: Charney Laurence N

Fri, 07 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260807/26892026.html

Form 4 TG THERAPEUTICS, INC. For: Aug 06 Filed by: Charney Laurence N

Fri, 07 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260807/26892026.html

TG Therapeutics (TGTX) PT Raised to $72 at JPMorgan

Fri, 07 Aug 2026 09:40:09 -0400

JPMorgan analyst Brian Cheng raised the price target on TG Therapeutics (NASDAQ: TGTX) to $72.00 (from $65.00) while maintaining a Overweight rating.

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -

- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -

- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -

- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -

- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Form 10-Q TG THERAPEUTICS, INC. For: Jun 30

Wed, 05 Aug 2026 17:01:00 -0400
si-local-file:///var/storage/secattach/20260805/26875648.html

Form 10-Q TG THERAPEUTICS, INC. For: Jun 30

Wed, 05 Aug 2026 17:01:00 -0400
si-local-file:///var/storage/secattach/20260805/26875648.html

TG Therapeutics (TGTX) PT Raised to $78 at H.C. Wainwright

Tue, 04 Aug 2026 06:51:30 -0400
(Updated - August 4, 2026 6:51 AM EDT)
H.C. Wainwright analyst Emily Bodnar raised the price target on TG Therapeutics (NASDAQ: TGTX) to $78.00 (from $77.00) while maintaining a Buy rating.
The analyst commented: "This morning, TG reported 2Q26 earnings and hosted a conference call. Briumvi US revenue in 2Q26 was $227.7M (up 17% QoQ), which was slightly above our estimate of $224M. Total revenues also included an $8.1M drug purchase from ex-US partner Neuraxpharm (private), and $4.5M in royalty and milestone revenues, leading to total revenue of $240.3M. Briumvi growth continues to be fueled by record new patient starts and switches

TG Therapeutics (TGTX) PT Raised to $78 at H.C. Wainwright

Tue, 04 Aug 2026 06:51:30 -0400
(Updated - August 4, 2026 6:51 AM EDT)
H.C. Wainwright analyst Emily Bodnar raised the price target on TG Therapeutics (NASDAQ: TGTX) to $78.00 (from $77.00) while maintaining a Buy rating.
The analyst commented: "This morning, TG reported 2Q26 earnings and hosted a conference call. Briumvi US revenue in 2Q26 was $227.7M (up 17% QoQ), which was slightly above our estimate of $224M. Total revenues also included an $8.1M drug purchase from ex-US partner Neuraxpharm (private), and $4.5M in royalty and milestone revenues, leading to total revenue of $240.3M. Briumvi growth continues to be fueled by record new patient starts and switches

Form 8-K TG THERAPEUTICS, INC. For: Aug 03

Mon, 03 Aug 2026 07:06:00 -0400
si-local-file:///var/storage/secattach/20260803/26853793.html

Form 8-K TG THERAPEUTICS, INC. For: Aug 03

Mon, 03 Aug 2026 07:06:00 -0400
si-local-file:///var/storage/secattach/20260803/26853793.html